AACR: Study Suggests Accelerated Approval Doesn’t Always Lead to Clinical Benefit

A recently published study suggests that many cancer drugs greenlit under the FDA’s accelerated approval pathway were given regulatory approval even though confirmatory studies failed to demonstrate clinical benefit in terms of quality of life or overall survival.